<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611921</url>
  </required_header>
  <id_info>
    <org_study_id>2015-2494</org_study_id>
    <nct_id>NCT02611921</nct_id>
  </id_info>
  <brief_title>Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder</brief_title>
  <official_title>Intranasal Ketamine Use in Autism Spectrum Disorder: A Placebo-Controlled Crossover Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roivant Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cures Within Reach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if intranasal ketamine shows initial evidence of&#xD;
      safety, tolerability and efficacy for the treatment of social impairment in individuals with&#xD;
      Autism Spectrum Disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To address the significant need for effective treatment of core symptoms of Autism Spectrum&#xD;
      Disorder (ASD), this trial is designed as a double-blind, placebo-controlled crossover pilot&#xD;
      study of intranasal ketamine in 24 individuals with ASD ages 12- 30 years using a novel&#xD;
      quantitative eye-tracking outcome measure to assess impact of the drug on social impairment.&#xD;
      Additionally, to develop a ketamine-focused personalized medicine approach in ASD, the&#xD;
      investigators will include pharmacokinetic, molecular pharmacodynamic, and&#xD;
      electrophysiological assessments into initial systematic study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 22, 2015</start_date>
  <completion_date type="Actual">May 7, 2018</completion_date>
  <primary_completion_date type="Actual">May 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Social Withdrawal subscale score of the Aberrant Behavior Checklist (ABC)</measure>
    <time_frame>Social withdrawal subscale change from baseline to final visit on day 35 ± 2 days</time_frame>
    <description>The ABC is the gold standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Clinician-rated CGI Improvement scale (CGI-I)</measure>
    <time_frame>CGI-I change from baseline to final visit on day 35 ± 2 days</time_frame>
    <description>The CGI-I is a 7-point scale designed to measure symptomatic change at a specific time as compared to baseline. The CGI-I will be focused on the target symptoms of social impairment. CGI-I is a gold standard measure of potential change with treatment in placebo- controlled pharmacotherapy trials in ASD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Crossover Group: Ketamine verses Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Two ascending doses of intranasal ketamine&#xD;
Two week washout&#xD;
Phase 2: Two doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Group: Placebo verses Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Two doses of placebo&#xD;
Two week washout&#xD;
Phase 2: Two ascending doses of intranasal ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator</description>
    <arm_group_label>Crossover Group: Ketamine verses Placebo</arm_group_label>
    <arm_group_label>Crossover Group: Placebo verses Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator</description>
    <arm_group_label>Crossover Group: Ketamine verses Placebo</arm_group_label>
    <arm_group_label>Crossover Group: Placebo verses Ketamine</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 12 to 30 years old.&#xD;
&#xD;
          -  Weight equal to or greater than 50 kg.&#xD;
&#xD;
          -  General good health as determined by physical exam, medical history, laboratory work&#xD;
             up, and EKG.&#xD;
&#xD;
          -  Diagnostic and Statistical Manual of Mental Disorders 5th Edition diagnosis of autism&#xD;
             spectrum disorder (not associated with Fragile X Syndrome or other known genetic&#xD;
             syndrome) as confirmed by the Autism Diagnostic Observation Schedule at screen or&#xD;
             previous (within last 5 years) if available.&#xD;
&#xD;
          -  Valid Intelligence Quotient (IQ) score greater than or equal to 50 as confirmed via&#xD;
             testing (Leiter-3) at screen or previous (within last 5 years, any valid testing&#xD;
             acceptable).&#xD;
&#xD;
          -  Clinical Global Impressions-Severity score of 4 (Moderately Ill).&#xD;
&#xD;
          -  Score of 10 on the Social Withdrawal subscale of the Aberrant Behavior Checklist.&#xD;
&#xD;
          -  Stable dosing of all concomitant psychotropic medications for five half-lives prior to&#xD;
             screening visit and during the study.&#xD;
&#xD;
          -  Presence of parent/guardian or significant other or caregiver willing to serve as&#xD;
             informant for behavioral outcome measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of co-morbid schizophrenia, schizoaffective disorder, bipolar disorder with&#xD;
             psychosis, bipolar disorder or psychosis not otherwise specified. Comorbid diagnoses&#xD;
             determined by psychiatrist clinical interview and use of Diagnostic and Statistical&#xD;
             Manual of Mental Disorders 5th Edition diagnostic criteria.&#xD;
&#xD;
          -  History of drug or alcohol abuse.&#xD;
&#xD;
          -  Presence of cardiac disease including coronary artery disease, congestive heart&#xD;
             failure, or uncontrolled hypertension per medical history (individuals with ≥ 2 blood&#xD;
             pressure readings of ≥140/90 during screen/baseline will be excluded).&#xD;
&#xD;
          -  Airway instability, tracheal surgery, or tracheal stenosis per medical history.&#xD;
&#xD;
          -  Central nervous system masses or hydrocephalus per medical history.&#xD;
&#xD;
          -  Porphyria, thyroid disorder, or thyroid medication use per medical history.&#xD;
&#xD;
          -  Glaucoma or other cause of increased intraocular pressure per medical history.&#xD;
&#xD;
          -  Allergy to ketamine.&#xD;
&#xD;
          -  Current use of drugs with concomitant modification of non-competitive&#xD;
             N-methyl-D-aspartate glutamate activity (acamprosate, amantadine, memantine,&#xD;
             d-cycloserine etc.)&#xD;
&#xD;
          -  For female subjects of child bearing potential, a positive pregnancy test.&#xD;
&#xD;
          -  Any major chronic medical or chronic respiratory illness considered to be uncontrolled&#xD;
             by the Principal Investigator.&#xD;
&#xD;
          -  Inability to tolerate study procedures or study drug per the discretion of the&#xD;
             Principal Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Logan K Wink, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Social Impairment</keyword>
  <keyword>Autism</keyword>
  <keyword>Autistic Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

